| answer text |
<p>Data on the costs of a particular condition, for which a medicine is prescribed,
is not collected. Information on the cost to the National Health Service of the medicines
listed under British National Formulary (BNF) section 10.1.4 - Gout and cytotoxic-induced
hyperuricaemia is shown in the table. These medicines include allopurinol, benzbromarone,
colchicine, febuxostat, probenecid and sulfinpyrazone.<strong> </strong>Rasburicase
is not included as it is used to treat cytotoxic-induced hyperuricaemia.</p><p> </p><p>
</p><p> </p><p>The BNF also states that acute attacks of gout are usually treated
with non-steroidal anti inflammatory drugs (NSAIDs) but, as it is not possible to
identify what proportion of the NSAIDs dispensed were used specifically for the treatment
of gout, these costs are not included.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Net
ingredient cost of drugs used in gout in primary and secondary care<sup>1</sup></p><p>£000s</p></td></tr><tr><td><p>2009</p></td><td><p>9,850.0</p></td></tr><tr><td><p>2010</p></td><td><p>12,449.7</p></td></tr><tr><td><p>2011</p></td><td><p>11,703.0</p></td></tr><tr><td><p>2012</p></td><td><p>14,445.3</p></td></tr><tr><td><p>2013</p></td><td><p>15,900.9</p></td></tr></tbody></table><p>
</p><p><em>Source:</em> Prescription Cost Analysis and IMS HEALTH: Hospital Pharmacy
Audit supplied by the Health and Social Care Information Centre</p><p> </p><p><strong>
</strong></p><p> </p><p><sup>1 </sup>The net ingredient cost does not include costs
associated with prescribing, dispensing and related activities, and excludes discounts
that may be applied.</p><p> </p><p><strong> </strong></p><p> </p>
|
|
